Skip to main content



Experimental and Therapeutic Studies

Inflammopharmacology OnlineFirst articles

30.11.2021 | Original Article

Metformin effect in models of inflammation is associated with activation of ATP-dependent potassium channels and inhibition of tumor necrosis factor-α production

Metformin is an oral hypoglycemic drug widely used in the management of type 2 diabetes mellitus. We have recently demonstrated that metformin exhibits activity in models of nociceptive and neuropathic pain. However, little is known about its …

26.11.2021 | Original Article

Myeloperoxidase as an important predictor of cardiovascular risk in individuals with rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory disease with great impact on the patient’s life and society health care, whose prevalence rate ranges from 0.55 to 1.0% in the world population. This disease preferentially affects women, with …

25.11.2021 | COVID-19 | Commentary Zur Zeit gratis

NSAIDs and Kelleni’s protocol as potential early COVID-19 treatment game changer: could it be the final countdown?

We have previously published several papers illustrating numerous immunomodulatory and anti-inflammatory potential benefits when we repurposed safe, generic non-steroidal anti-inflammatory drugs (NSAIDs)/nitazoxanide/azithromycin (Kelleni’s …

23.11.2021 | Review

Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer’s disease

Alzheimer’s disease (AD) is a major contributor of dementia leading to the degeneration of neurons in the brain with major symptoms like loss of memory and learning. Many evidences suggest the involvement of neuroinflammation in the pathology of …

23.11.2021 | Review

Cardiac inflammation and fibrosis following chemo/radiation therapy: mechanisms and therapeutic agents

The incidence of cardiovascular disorders is one of the most concerns among people who underwent cancer therapy. The heart side effects of cancer therapy may occur during treatment to some years after the end of treatment. Some epidemiological …

Aktuelle Ausgaben

Über diese Zeitschrift

Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS).

Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn's disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle.

The journal has six main interest areas:

  • Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states
  • Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs
  • Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents
  • Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain
  • Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs
  • Muscle-immune interactions during inflammation: mechanisms of inflammation and anti-inflammatory actions of therapeutic agents on skeletal muscle under conditions of aging or injury.

Requirements for manuscripts on the pharmacological or inflammatory properties of natural products are described in the editorial Inflammopharmacology Vol. 15, issue 5 or on the journal website:

Weitere Informationen